|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CTR9 |
Gene summary for CTR9 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CTR9 | Gene ID | 9646 |
| Gene name | CTR9 homolog, Paf1/RNA polymerase II complex component | |
| Gene Alias | SH2BP1 | |
| Cytomap | 11p15.4 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q6PD62 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9646 | CTR9 | LZE4T | Human | Esophagus | ESCC | 3.11e-08 | 3.17e-01 | 0.0811 |
| 9646 | CTR9 | LZE7T | Human | Esophagus | ESCC | 2.34e-10 | 2.08e-01 | 0.0667 |
| 9646 | CTR9 | LZE8T | Human | Esophagus | ESCC | 1.53e-04 | -8.57e-02 | 0.067 |
| 9646 | CTR9 | LZE20T | Human | Esophagus | ESCC | 1.17e-02 | 4.91e-02 | 0.0662 |
| 9646 | CTR9 | LZE22T | Human | Esophagus | ESCC | 1.05e-02 | 2.73e-02 | 0.068 |
| 9646 | CTR9 | LZE24T | Human | Esophagus | ESCC | 1.63e-13 | 3.91e-01 | 0.0596 |
| 9646 | CTR9 | LZE21T | Human | Esophagus | ESCC | 3.49e-03 | 9.21e-04 | 0.0655 |
| 9646 | CTR9 | P1T-E | Human | Esophagus | ESCC | 5.18e-07 | 1.12e-01 | 0.0875 |
| 9646 | CTR9 | P2T-E | Human | Esophagus | ESCC | 3.63e-18 | 4.19e-01 | 0.1177 |
| 9646 | CTR9 | P4T-E | Human | Esophagus | ESCC | 7.03e-18 | 3.32e-01 | 0.1323 |
| 9646 | CTR9 | P5T-E | Human | Esophagus | ESCC | 5.15e-08 | 5.54e-02 | 0.1327 |
| 9646 | CTR9 | P8T-E | Human | Esophagus | ESCC | 1.34e-21 | 4.24e-02 | 0.0889 |
| 9646 | CTR9 | P9T-E | Human | Esophagus | ESCC | 1.19e-19 | 2.79e-01 | 0.1131 |
| 9646 | CTR9 | P10T-E | Human | Esophagus | ESCC | 2.05e-16 | 2.87e-01 | 0.116 |
| 9646 | CTR9 | P11T-E | Human | Esophagus | ESCC | 3.35e-11 | 7.81e-01 | 0.1426 |
| 9646 | CTR9 | P12T-E | Human | Esophagus | ESCC | 5.41e-17 | 4.99e-02 | 0.1122 |
| 9646 | CTR9 | P15T-E | Human | Esophagus | ESCC | 2.29e-22 | 5.11e-01 | 0.1149 |
| 9646 | CTR9 | P16T-E | Human | Esophagus | ESCC | 1.81e-16 | 2.88e-01 | 0.1153 |
| 9646 | CTR9 | P17T-E | Human | Esophagus | ESCC | 9.99e-06 | 1.90e-01 | 0.1278 |
| 9646 | CTR9 | P20T-E | Human | Esophagus | ESCC | 1.17e-15 | 2.89e-01 | 0.1124 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:019873815 | Oral cavity | LP | cell-cell signaling by wnt | 140/4623 | 446/18723 | 7.12e-04 | 6.38e-03 | 140 |
| GO:001657413 | Oral cavity | LP | histone ubiquitination | 22/4623 | 47/18723 | 8.02e-04 | 7.05e-03 | 22 |
| GO:003144012 | Oral cavity | LP | regulation of mRNA 3'-end processing | 15/4623 | 28/18723 | 9.65e-04 | 8.17e-03 | 15 |
| GO:003105613 | Oral cavity | LP | regulation of histone modification | 55/4623 | 152/18723 | 1.01e-03 | 8.48e-03 | 55 |
| GO:000223718 | Oral cavity | LP | response to molecule of bacterial origin | 115/4623 | 363/18723 | 1.42e-03 | 1.13e-02 | 115 |
| GO:00310581 | Oral cavity | LP | positive regulation of histone modification | 36/4623 | 92/18723 | 1.51e-03 | 1.18e-02 | 36 |
| GO:00103901 | Oral cavity | LP | histone monoubiquitination | 15/4623 | 29/18723 | 1.55e-03 | 1.20e-02 | 15 |
| GO:007122214 | Oral cavity | LP | cellular response to lipopolysaccharide | 69/4623 | 209/18723 | 3.99e-03 | 2.59e-02 | 69 |
| GO:190370619 | Oral cavity | LP | regulation of hemopoiesis | 111/4623 | 367/18723 | 8.48e-03 | 4.60e-02 | 111 |
| GO:190331116 | Prostate | BPH | regulation of mRNA metabolic process | 111/3107 | 288/18723 | 2.28e-19 | 1.17e-16 | 111 |
| GO:005068415 | Prostate | BPH | regulation of mRNA processing | 64/3107 | 137/18723 | 1.73e-16 | 3.82e-14 | 64 |
| GO:190332018 | Prostate | BPH | regulation of protein modification by small protein conjugation or removal | 90/3107 | 242/18723 | 7.37e-15 | 1.01e-12 | 90 |
| GO:003009918 | Prostate | BPH | myeloid cell differentiation | 115/3107 | 381/18723 | 2.22e-11 | 1.51e-09 | 115 |
| GO:003139618 | Prostate | BPH | regulation of protein ubiquitination | 74/3107 | 210/18723 | 3.66e-11 | 2.39e-09 | 74 |
| GO:00160559 | Prostate | BPH | Wnt signaling pathway | 126/3107 | 444/18723 | 2.27e-10 | 1.23e-08 | 126 |
| GO:01987389 | Prostate | BPH | cell-cell signaling by wnt | 126/3107 | 446/18723 | 3.11e-10 | 1.67e-08 | 126 |
| GO:000170110 | Prostate | BPH | in utero embryonic development | 104/3107 | 367/18723 | 9.17e-09 | 3.10e-07 | 104 |
| GO:190331218 | Prostate | BPH | negative regulation of mRNA metabolic process | 38/3107 | 92/18723 | 1.63e-08 | 5.11e-07 | 38 |
| GO:00165706 | Prostate | BPH | histone modification | 120/3107 | 463/18723 | 1.73e-07 | 3.89e-06 | 120 |
| GO:00506868 | Prostate | BPH | negative regulation of mRNA processing | 17/3107 | 29/18723 | 3.61e-07 | 7.60e-06 | 17 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CTR9 | SNV | Missense_Mutation | c.2140C>G | p.His714Asp | p.H714D | Q6PD62 | protein_coding | deleterious(0.02) | benign(0.003) | TCGA-A8-A06O-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | letrozole | SD | |
| CTR9 | SNV | Missense_Mutation | c.493N>A | p.Ala165Thr | p.A165T | Q6PD62 | protein_coding | deleterious(0.01) | probably_damaging(0.943) | TCGA-AR-A0TZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | Doxorubicin | PD | |
| CTR9 | SNV | Missense_Mutation | c.2311N>A | p.Asp771Asn | p.D771N | Q6PD62 | protein_coding | tolerated(0.15) | benign(0.012) | TCGA-AR-A256-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD | |
| CTR9 | SNV | Missense_Mutation | rs777109871 | c.1555N>G | p.Leu519Val | p.L519V | Q6PD62 | protein_coding | deleterious(0.03) | benign(0.376) | TCGA-B6-A0IJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CTR9 | SNV | Missense_Mutation | c.2239N>A | p.Ala747Thr | p.A747T | Q6PD62 | protein_coding | deleterious(0.01) | benign(0.122) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| CTR9 | insertion | Frame_Shift_Ins | novel | c.783_784insACCTTTG | p.Tyr262ThrfsTer6 | p.Y262Tfs*6 | Q6PD62 | protein_coding | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD | ||
| CTR9 | insertion | Nonsense_Mutation | novel | c.1373_1374insATAAAAGAGAT | p.Ala459Ter | p.A459* | Q6PD62 | protein_coding | TCGA-AR-A0U2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | PD | ||
| CTR9 | SNV | Missense_Mutation | rs760130762 | c.1427N>T | p.Ala476Val | p.A476V | Q6PD62 | protein_coding | tolerated(0.28) | benign(0.083) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CTR9 | SNV | Missense_Mutation | c.2732N>G | p.Ser911Cys | p.S911C | Q6PD62 | protein_coding | deleterious(0.03) | probably_damaging(0.971) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | |
| CTR9 | SNV | Missense_Mutation | novel | c.2680G>A | p.Glu894Lys | p.E894K | Q6PD62 | protein_coding | tolerated(0.86) | benign(0.05) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |